The global cellular reprogramming tools market is witnessing robust growth, reaching USD 456.1 million in 2024 and expected to climb to USD 760.1 million by 2034 at a CAGR of 5.24% (2025–2034). This surge is fueled by the adoption of CRISPR gene editing, small molecule modulators, and AI-based solutions in regenerative medicine, disease modeling, and drug discovery.
North America holds a dominant 45% market share in 2024, while Asia-Pacific is poised for the fastest growth. Among product types, reprogramming vectors and reagents account for 50% of the revenue.
Below, we explore the top companies shaping the cellular reprogramming tools market, including their background, key offerings, and market capitalization.
About: Thermo Fisher Scientific is a global leader in life sciences, providing innovative solutions to accelerate research and improve healthcare outcomes.
Products: It offers an extensive portfolio of reprogramming vectors, stem cell culture reagents, and CRISPR-Cas9 tools.
Market Cap: Approx. USD 240 billion.
About: Lonza is a Swiss multinational specializing in pharma and biotech manufacturing services.
Products: Known for cell therapy manufacturing platforms, reprogramming tools, and gene editing services.
Market Cap: Approx. USD 40 billion.
About: Merck’s MilliporeSigma division focuses on life science solutions and advanced reprogramming technologies.
Products: Offers reprogramming kits, genome editing tools, and pluripotent stem cell reagents.
Market Cap: Approx. USD 20 billion.
About: A Canadian biotech company specializing in high-quality tools for stem cell and regenerative medicine research.
Products: Provides reagents, culture media, and reprogramming systems for iPSC generation.
Market Cap: Privately held (estimated revenue over USD 500 million).
About: Bio-Techne develops reagents, instruments, and services supporting cellular and gene therapy workflows.
Products: Includes CRISPR-related tools and cytokines for reprogramming applications.
Market Cap: Approx. USD 12 billion.
About: Takara Bio is a Japanese biotechnology firm leading in genetic engineering and stem cell technologies.
Products: Offers reprogramming kits, retroviral vectors, and CRISPR systems.
Market Cap: Approx. USD 2.8 billion.
About: Sartorius provides equipment and solutions for the biopharmaceutical industry.
Products: Includes cell culture systems and tools enabling cellular reprogramming workflows.
Market Cap: Approx. USD 20 billion.
About: A subsidiary of Fujifilm, this company specializes in iPSC technologies and cell therapy solutions.
Products: Supplies reprogrammed iPSCs and differentiation kits for research and clinical use.
Market Cap: Part of Fujifilm Holdings (USD 30 billion market cap).
About: German company offering innovative solutions for cell and gene therapy research.
Products: Reprogramming vectors, cell isolation tools, and magnetic-activated cell sorting systems.
Market Cap: Privately held.
About: Known for high-quality antibodies and reagents in cell biology and signal transduction.
Products: Offers reagents supporting reprogramming and pluripotency research.
Market Cap: Privately held (estimated revenue over USD 400 million).
About: Cytiva, under GE Healthcare, delivers bioprocessing solutions and cellular reprogramming tools.
Products: Includes culture systems, reagents, and gene editing tools for reprogramming.
Market Cap: Part of GE HealthCare (USD 45 billion market cap).
About: A gene editing company enabling precision cell engineering for drug discovery.
Products: Provides CRISPR reagents and reprogramming tools for creating disease models.
Market Cap: Approx. USD 300 million (acquired by PerkinElmer).
About: A global leader in gene synthesis and CRISPR-related solutions.
Products: Includes vectors, enzymes, and reagents for cellular reprogramming workflows.
Market Cap: Approx. USD 4 billion.
About: Abcam is a global supplier of protein research tools for life science research.
Products: Offers antibodies and reagents supporting iPSC and reprogramming research.
Market Cap: Approx. USD 2 billion.
About: Novellus focuses on cellular reprogramming technologies for oncology applications.
Products: Develops proprietary reprogramming systems for generating immune cell therapies.
Market Cap: Privately held.
About: A clinical-stage biopharmaceutical company specializing in gene-editing-based therapies.
Products: Uses TALEN and CRISPR platforms for cellular reprogramming.
Market Cap: Approx. USD 200 million.
About: A nonprofit plasmid repository supporting global research in genetic engineering.
Products: Offers thousands of plasmids for CRISPR and reprogramming research.
Market Cap: Nonprofit.
About: IDT delivers custom nucleic acids and gene editing solutions.
Products: CRISPR kits, synthetic genes, and reagents for cellular reprogramming.
Market Cap: Part of Danaher Corporation (USD 200 billion market cap).
With CRISPR technologies, small molecule enhancers, and AI-driven discoveries, cellular reprogramming tools are at the forefront of biotech innovation. As companies scale their platforms and expand into clinical applications, this market is set to reshape personalized medicine, drug development, and regenerative therapies globally.
Source : https://www.towardshealthcare.com/insights/cellular-reprogramming-tools-market-sizing
The global human microbiome market was valued at USD 0.94 billion in 2024, projected to reach USD 1.23 billion in… Read More
The europe infection control market was valued at USD 14.17 billion in 2024, projected to reach USD 15.1 billion in… Read More
The global antimalarial drugs market was valued at USD 1.07 billion in 2024, grew to USD 1.12 billion in 2025,… Read More
The global IoT medical devices market was valued at USD 82.45 billion in 2024, expanded to USD 105.54 billion in… Read More
The global dental consumables market was valued at USD 40.7 billion in 2024, projected to grow to USD 42.92 billion… Read More
The global suppositories market was valued at USD 1.6 billion in 2024, increasing to USD 1.68 billion in 2025, and… Read More